-
Je něco špatně v tomto záznamu ?
The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study
WJ. van Weelden, C. Reijnen, HVN. Küsters-Vandevelde, J. Bulten, P. Bult, S. Leung, NCM. Visser, M. Santacana, P. Bronsert, M. Hirschfeld, E. Colas, A. Gil-Moreno, A. Reques, G. Mancebo, J. Huvila, M. Koskas, V. Weinberger, M. Bednarikova, J....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- doba přežití bez progrese choroby MeSH
- estrogeny metabolismus MeSH
- lidé MeSH
- nádorové biomarkery metabolismus MeSH
- nádory endometria diagnóza metabolismus patologie MeSH
- přežití po terapii bez příznaků nemoci MeSH
- prognóza MeSH
- receptory pro estrogeny metabolismus MeSH
- receptory progesteronu metabolismus MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
There is no consensus on the cutoff for positivity of estrogen receptor (ER) and progesterone receptor (PR) in endometrial cancer (EC). Therefore, we determined the cutoff value for ER and PR expression with the strongest prognostic impact on the outcome. Immunohistochemical expression of ER and PR was scored as a percentage of positive EC cell nuclei. Cutoff values were related to disease-specific survival (DSS) and disease-free survival (DFS) using sensitivity, specificity, and multivariable regression analysis. The results were validated in an independent cohort. The study cohort (n = 527) included 82% of grade 1-2 and 18% of grade 3 EC. Specificity for DSS and DFS was highest for the cutoff values of 1-30%. Sensitivity was highest for the cutoff values of 80-90%. ER and PR expression were independent markers for DSS at cutoff values of 10% and 80%. Consequently, three subgroups with distinct clinical outcomes were identified: 0-10% of ER/PR expression with, unfavorable outcome (5-year DSS = 75.9-83.3%); 20-80% of ER/PR expression with, intermediate outcome (5-year DSS = 93.0-93.9%); and 90-100% of ER/PR expression with, favorable outcome (5-year DSS = 97.8-100%). The association between ER/PR subgroups and outcomes was confirmed in the validation cohort (n = 265). We propose classification of ER and PR expression based on a high-risk (0-10%), intermediate-risk (20-80%), and low-risk (90-100%) group.
Department of Obstetrics and Gynecology Hospital del Mar PSMAR 08003 Barcelona Spain
Department of Obstetrics and Gynecology University Medical Center 79106 Freiburg Germany
Department of Oncology KU Leuven 3000 Leuven Belgium
Department of Pathology Canisius Wilhelmina Hospital Nijmegen 6532 SZ the Netherlands
Department of Pathology Radboud University Medical Center Nijmegen 6525 GA the Netherlands
Department of Pathology University of Turku 20500 Turku Finland
Foundation Laboratory for Pathology and Medical Microbiology 5623 EJ Eindhoven the Netherlands
Gynecological Department Vall Hebron University Hospital CIBERONC 08035 Barcelona Spain
Institute of Pathology Faculty of Medicine Masaryk University 62500 Brno Czech Republic
Institute of Pathology University Medical Center 79106 Freiburg Germany
Institute of Veterinary Medicine Georg August University 37073 Goettingen Germany
Obstetrics and Gynecology Department Bichat Claude Bernard Hospital 75018 Paris France
Pathology Department Vall Hebron University Hospital CIBERONC 08035 Barcelona Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026019
- 003
- CZ-PrNML
- 005
- 20211026133254.0
- 007
- ta
- 008
- 211013s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.humpath.2020.12.003 $2 doi
- 035 __
- $a (PubMed)33338506
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a van Weelden, Willem Jan $u Department of Obstetrics and Gynaecology, Radboud University Medical Center, 6525, GA, Nijmegen, the Netherlands. Electronic address: willemjan.vanweelden@radboudumc.nl
- 245 14
- $a The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study / $c WJ. van Weelden, C. Reijnen, HVN. Küsters-Vandevelde, J. Bulten, P. Bult, S. Leung, NCM. Visser, M. Santacana, P. Bronsert, M. Hirschfeld, E. Colas, A. Gil-Moreno, A. Reques, G. Mancebo, J. Huvila, M. Koskas, V. Weinberger, M. Bednarikova, J. Hausnerova, MPLM. Snijders, X. Matias-Guiu, F. Amant, ENITEC-Consortium
- 520 9_
- $a There is no consensus on the cutoff for positivity of estrogen receptor (ER) and progesterone receptor (PR) in endometrial cancer (EC). Therefore, we determined the cutoff value for ER and PR expression with the strongest prognostic impact on the outcome. Immunohistochemical expression of ER and PR was scored as a percentage of positive EC cell nuclei. Cutoff values were related to disease-specific survival (DSS) and disease-free survival (DFS) using sensitivity, specificity, and multivariable regression analysis. The results were validated in an independent cohort. The study cohort (n = 527) included 82% of grade 1-2 and 18% of grade 3 EC. Specificity for DSS and DFS was highest for the cutoff values of 1-30%. Sensitivity was highest for the cutoff values of 80-90%. ER and PR expression were independent markers for DSS at cutoff values of 10% and 80%. Consequently, three subgroups with distinct clinical outcomes were identified: 0-10% of ER/PR expression with, unfavorable outcome (5-year DSS = 75.9-83.3%); 20-80% of ER/PR expression with, intermediate outcome (5-year DSS = 93.0-93.9%); and 90-100% of ER/PR expression with, favorable outcome (5-year DSS = 97.8-100%). The association between ER/PR subgroups and outcomes was confirmed in the validation cohort (n = 265). We propose classification of ER and PR expression based on a high-risk (0-10%), intermediate-risk (20-80%), and low-risk (90-100%) group.
- 650 _2
- $a nádorové biomarkery $x metabolismus $7 D014408
- 650 _2
- $a přežití po terapii bez příznaků nemoci $7 D018572
- 650 _2
- $a nádory endometria $x diagnóza $x metabolismus $x patologie $7 D016889
- 650 _2
- $a estrogeny $x metabolismus $7 D004967
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 _2
- $a receptory pro estrogeny $x metabolismus $7 D011960
- 650 _2
- $a receptory progesteronu $x metabolismus $7 D011980
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Reijnen, Casper $u Department of Obstetrics and Gynaecology, Radboud University Medical Center, 6525, GA, Nijmegen, the Netherlands; Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, Nijmegen, 6532, SZ, the Netherlands
- 700 1_
- $a Küsters-Vandevelde, Heidi V N $u Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen, 6532, SZ, the Netherlands
- 700 1_
- $a Bulten, Johan $u Department of Pathology, Radboud University Medical Center, Nijmegen, 6525, GA, the Netherlands
- 700 1_
- $a Bult, Peter $u Department of Pathology, Radboud University Medical Center, Nijmegen, 6525, GA, the Netherlands
- 700 1_
- $a Leung, Samuel $u Genetic Pathology Evaluation Center, Vancouver General Hospital, Vancouver, BC V5Z 1M9, British Columbia, Canada
- 700 1_
- $a Visser, Nicole C M $u Foundation Laboratory for Pathology and Medical Microbiology (PAMM), 5623 EJ, Eindhoven, the Netherlands
- 700 1_
- $a Santacana, Maria $u Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, CIBERONC, 25198, Lleida, Spain
- 700 1_
- $a Bronsert, Peter $u Institute of Pathology, University Medical Center, 79106, Freiburg, Germany
- 700 1_
- $a Hirschfeld, Marc $u Department of Obstetrics and Gynecology, University Medical Center, 79106, Freiburg, Germany; Institute of Veterinary Medicine, Georg-August-University, 37073, Goettingen, Germany
- 700 1_
- $a Colas, Eva $u Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, Universitat Autònoma de Barcelona, CIBERONC, 08035, Barcelona, Spain
- 700 1_
- $a Gil-Moreno, Antonio $u Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, Universitat Autònoma de Barcelona, CIBERONC, 08035, Barcelona, Spain; Gynecological Department, Vall Hebron University Hospital, CIBERONC, 08035, Barcelona, Spain
- 700 1_
- $a Reques, Armando $u Pathology Department, Vall Hebron University Hospital, CIBERONC, 08035, Barcelona, Spain
- 700 1_
- $a Mancebo, Gemma $u Department of Obstetrics and Gynecology, Hospital del Mar, PSMAR, 08003, Barcelona, Spain
- 700 1_
- $a Huvila, Jutta $u Department of Pathology, University of Turku, 20500, Turku, Finland
- 700 1_
- $a Koskas, Martin $u Obstetrics and Gynecology Department, Bichat-Claude Bernard Hospital, 75018, Paris, France
- 700 1_
- $a Weinberger, Vit $u Department of Gynecology and Obstetrics, Faculty of Medicine, Masaryk University, 62500, Brno, Czech Republic
- 700 1_
- $a Bednarikova, Marketa $u Department of Internal Medicine, Oncology and Hematology, Faculty of Medicine, Masaryk University, 62500, Brno, Czech Republic
- 700 1_
- $a Hausnerova, Jitka $u Institute of Pathology, Faculty of Medicine, Masaryk University, 62500, Brno, Czech Republic
- 700 1_
- $a Snijders, Marc P L M $u Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, Nijmegen, 6532, SZ, the Netherlands
- 700 1_
- $a Matias-Guiu, Xavier $u Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, CIBERONC, 25198, Lleida, Spain
- 700 1_
- $a Amant, Frédéric $u Department of Oncology, KU Leuven, 3000, Leuven, Belgium; Center for Gynaecologic Oncology, Netherlands Cancer Institute and Amsterdam University Medical Center, 1066, CX, Amsterdam, the Netherlands
- 710 2_
- $a ENITEC-Consortium
- 773 0_
- $w MED00002080 $t Human pathology $x 1532-8392 $g Roč. 109, č. - (2021), s. 80-91
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33338506 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133300 $b ABA008
- 999 __
- $a ok $b bmc $g 1714895 $s 1146526
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 109 $c - $d 80-91 $e 20201215 $i 1532-8392 $m Human pathology $n Hum Pathol $x MED00002080
- LZP __
- $a Pubmed-20211013
